Literature DB >> 10999744

Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis.

K Okada1, K Komuta, S Hashimoto, S Matsuzaki, T Kanematsu, T Koji.   

Abstract

We investigated apoptosis in tumor-infiltrating lymphocytes (TILs) obtained from 41 colorectal carcinomas by in situ nick translation (ISNT). When the ISNT labeling index (LI) was determined as the number of positive nuclei per 1000 nuclei of TIL in tissue sections, the median LI was 12.0 (range, 2-30). The ISNT LI of colorectal carcinoma with lymph node metastasis was higher than that of colorectal carcinoma without metastasis. The cases with a high LI of 212.0 had a significantly poorer prognosis than those with a low LI. We also confirmed immunohistochemically that a part of the TILs expressed Fas using the sections adjacent to what contained abundant ISNT-positive TILs. Moreover, Fas ligand (FasL) expression was detected on the cell surface as well as the cytoplasm of colorectal cancer cells in 61% of cases. Apoptosis in TILs was consistently seen more frequently in FasL-positive cases than in FasL-negative ones. These findings indicate that the FasL expressed in colorectal carcinoma cells may kill the Fas-positive immune effective TILs by means of a Fas-FasL system termed Fas counterattack. This tumor immune evasion induced by FasL may therefore affect the malignant potential of human colorectal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10999744

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  27 in total

Review 1.  Fas ligand and the fate of antitumour cytotoxic T lymphocytes.

Authors:  Joe O'Connell
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

2.  Weapons ovarian epithelial tumors may use in immune escape: an immunohistochemical correlational study.

Authors:  Eiman Adel Hasby
Journal:  Pathol Oncol Res       Date:  2011-12-08       Impact factor: 3.201

3.  The Fas-FasL system and colorectal tumours.

Authors:  C A Rubio; B Jacobsson
Journal:  J Clin Pathol       Date:  2002-07       Impact factor: 3.411

4.  Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.

Authors:  Qiang Zhu; Ji-Yong Liu; Hong-Wei Xu; Chong-Mei Yang; An-Zhong Zhang; Yi Cui; Hong-Bo Wang
Journal:  World J Gastroenterol       Date:  2005-10-21       Impact factor: 5.742

5.  Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies.

Authors:  Mariana Rodríguez Zubieta; David Furman; Marcela Barrio; Alicia Inés Bravo; Enzo Domenichini; José Mordoh
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

Review 6.  Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients.

Authors:  Kristen M Drescher; Poonam Sharma; Henry T Lynch
Journal:  Clin Dev Immunol       Date:  2010-06-10

7.  Corticotropin-releasing hormone (CRH) is expressed in the human cervical carcinoma cells (HeLa) and upregulates the expression of Fas ligand.

Authors:  Eirini Taliouri; Thomas Vrekoussis; Aikaterini Vergetaki; Theodore Agorastos; Antonis Makrigiannakis
Journal:  Tumour Biol       Date:  2012-10-18

8.  Retinoic acid morpholine amide (RAMA) inhibits expression of Fas ligand through EP1 receptor in colon cancer cells.

Authors:  Shao-Xuan Chen; Shi-Yu Du; Yun-Ting Wang; Hong-Chuan Zhao; Yan-Li Zhang; Li Yao
Journal:  Tumour Biol       Date:  2015-07-27

9.  Expression of TNF-related apoptosis-inducing ligand (TRAIL) in keratinocytes mediates apoptotic cell death in allogenic T cells.

Authors:  Kerstin Reimers; Christine Radtke; Claudia Y Choi; Christina Allmeling; Susanne Kall; Paul Kiefer; Thomas Muehlberger; Peter M Vogt
Journal:  Ann Surg Innov Res       Date:  2009-11-19

10.  Fas ligand expression in lynch syndrome-associated colorectal tumours.

Authors:  Jan J Koornstra; Steven de Jong; Wietske Boersma-van Eck; Nynke Zwart; Harry Hollema; Elisabeth G E de Vries; Jan H Kleibeuker
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.